elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Chemotherapy
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Chemotherapy
RIS
0.017
(Research Intensity Score)
Papers
2191
Top papers
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · 972 citations
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
2022 · 2627 citations
Glioblastoma and Other Primary Brain Malignancies in Adults
2023 · 1204 citations
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
2023 · 1074 citations
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
2023 · 681 citations
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
2024 · 350 citations
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2025 · 214 citations
Gastric cancer
2020 · 4911 citations
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
2023 · 749 citations
Newest papers
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2025 · 214 citations
Small Cell Lung Cancer
2025 · 158 citations
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
2025 · 115 citations
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2025 · 77 citations
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2025 · 76 citations
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
2025 · 69 citations
NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.
2025 · 58 citations
Head and Neck Cancer
2025 · 43 citations
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial
2025 · 53 citations
Browse all papers →
Chemotherapy's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Chemotherapy's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link